AstraZenecas Enhertu sBLA Gets FDA Priority Tag for Expanded Use
The FDA grants priority review to AZNs sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A decision…
64,000€
-0,39%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
Novos Tough Month Key in Ending Health Stocks Winning Streak
European health-care stocks are set to snap their longest winning streak since March 2010, dragged down by concerns over Novo…
The Zacks Analyst Blog Highlights Toyota Motor, AstraZeneca, Chubb, Air T and Preformed Line Products
Toyota Motor, AstraZeneca, Chubb, Air T and Preformed Line Products are part of the Zacks top Analyst Blog.…
Tagrisso US approval in unresectable lung cancer
26 September 2024
Tagrisso approved in the US for patients with
unresectable, Stage III EGFR-mutated lung cancer
Based on LAURA Phase III trial results which showed Tagrisso
extended…
AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy?
AZNs key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga are likely to drive sales. It has several candidates with…